Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

The FDA has paused a study of Amgen’s early-stage candidate AMG 513. Elsewhere, Valneva got another approval and a radiopharma developer raised $112 million.

The Lipodystrophy market growth is driven by factors like increase in the prevalence of Lipodystrophy, investments in research and development, entry of emerging therapies during the study period 2020 ...

Genentech Inc. won regulatory approval Tuesday to market an eye implant that can be refilled every six months with an already ...

Sales of Eylea, which the company co-developed with Bayer (DE:BAYA), rose 2% to $1.495 billion. Sales of the higher-dose, longer-lasting formulation Eylea HD rose 148% to $305 million in the U.S., ...

Diabetic Macular Edema MarketThe global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to ...

Forty high school students, including four from Nassau County, have been selected as finalists for the annual Regeneron ...

Diabetes can lead to complications throughout the body and commonly causes digestive disorders such as gastroparesis (delayed emptying of the stomach). This can lead to stomach problems and pain.

In most cases, people with type 2 diabetes can drink alcohol in moderate amounts. As you may well know, living with type 2 diabetes often means cutting out or cutting back on foods and beverages that ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals ... which have the potential to treat more conditions beyond diabetes and weight loss. Additionally, companies are ...